CY1121650T1 - Αναστολεις συνθασης αλδοστερονης - Google Patents

Αναστολεις συνθασης αλδοστερονης

Info

Publication number
CY1121650T1
CY1121650T1 CY20191100554T CY191100554T CY1121650T1 CY 1121650 T1 CY1121650 T1 CY 1121650T1 CY 20191100554 T CY20191100554 T CY 20191100554T CY 191100554 T CY191100554 T CY 191100554T CY 1121650 T1 CY1121650 T1 CY 1121650T1
Authority
CY
Cyprus
Prior art keywords
compounds
synthesis inhibitors
aldosterone synthesis
processes
relates
Prior art date
Application number
CY20191100554T
Other languages
Greek (el)
English (en)
Inventor
Keith R. Hornberger
Kenneth Michael MEYERS
Peter Allen Nemoto
Simon Surprenant
Hui Yu
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54352516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121650(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1121650T1 publication Critical patent/CY1121650T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/54Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20191100554T 2014-10-15 2019-05-24 Αναστολεις συνθασης αλδοστερονης CY1121650T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064234P 2014-10-15 2014-10-15
PCT/US2015/055421 WO2016061161A1 (en) 2014-10-15 2015-10-14 Aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
CY1121650T1 true CY1121650T1 (el) 2020-07-31

Family

ID=54352516

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100554T CY1121650T1 (el) 2014-10-15 2019-05-24 Αναστολεις συνθασης αλδοστερονης

Country Status (33)

Country Link
US (1) US9745289B2 (enExample)
EP (1) EP3207039B1 (enExample)
JP (1) JP6279812B2 (enExample)
KR (1) KR102441634B1 (enExample)
CN (1) CN107108587B (enExample)
AP (1) AP2017009829A0 (enExample)
AR (1) AR102266A1 (enExample)
AU (1) AU2015333611B2 (enExample)
CA (1) CA2964754C (enExample)
CL (1) CL2017000827A1 (enExample)
CO (1) CO2017003305A2 (enExample)
CY (1) CY1121650T1 (enExample)
DK (1) DK3207039T3 (enExample)
EA (1) EA031766B1 (enExample)
ES (1) ES2724555T3 (enExample)
HR (1) HRP20190896T1 (enExample)
HU (1) HUE043783T2 (enExample)
IL (1) IL251200B (enExample)
LT (1) LT3207039T (enExample)
ME (1) ME03381B (enExample)
MX (1) MX369025B (enExample)
NZ (1) NZ729688A (enExample)
PE (1) PE20170696A1 (enExample)
PH (1) PH12017500595B1 (enExample)
PL (1) PL3207039T3 (enExample)
PT (1) PT3207039T (enExample)
RS (1) RS58651B1 (enExample)
SG (1) SG11201701850UA (enExample)
SI (1) SI3207039T1 (enExample)
TR (1) TR201907755T4 (enExample)
TW (1) TWI731842B (enExample)
UA (1) UA118717C2 (enExample)
WO (1) WO2016061161A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890171B2 (en) * 2014-12-02 2018-02-13 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
EP3562487B1 (en) * 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7530384B2 (ja) 2019-05-01 2024-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング (r)-(2-メチルオキシラン-2-イル)メチル 4-ブロモベンゼンスルホネート
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
TW202339719A (zh) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療慢性腎臟病之醛固酮合成酶抑制劑
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
CN121181527A (zh) * 2024-06-21 2025-12-23 江苏豪森药业集团有限公司 双稠环类化合物、及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201026688A (en) * 2008-10-07 2010-07-16 Schering Corp Benzodioxan analogues as alpha2C adrenergic receptor modulators
JP5659224B2 (ja) * 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
AR088989A1 (es) * 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
JP6496246B2 (ja) * 2012-10-05 2019-04-03 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
BR112015019836A2 (pt) * 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
HUE039981T2 (hu) * 2014-07-24 2019-02-28 Boehringer Ingelheim Int Aldoszteron szintáz inhibitorok

Also Published As

Publication number Publication date
CO2017003305A2 (es) 2017-07-19
HRP20190896T1 (hr) 2019-07-12
PE20170696A1 (es) 2017-06-07
JP6279812B2 (ja) 2018-02-14
CN107108587A (zh) 2017-08-29
LT3207039T (lt) 2019-05-10
KR102441634B1 (ko) 2022-09-13
EA031766B1 (ru) 2019-02-28
AU2015333611B2 (en) 2020-02-06
ME03381B (me) 2020-01-20
MX2017004852A (es) 2017-06-22
AR102266A1 (es) 2017-02-15
AP2017009829A0 (en) 2017-03-31
RS58651B1 (sr) 2019-05-31
EP3207039B1 (en) 2019-03-06
UA118717C2 (uk) 2019-02-25
MX369025B (es) 2019-10-25
SG11201701850UA (en) 2017-04-27
TWI731842B (zh) 2021-07-01
WO2016061161A1 (en) 2016-04-21
JP2017531016A (ja) 2017-10-19
US9745289B2 (en) 2017-08-29
CL2017000827A1 (es) 2017-11-03
PH12017500595B1 (en) 2020-11-25
SI3207039T1 (sl) 2019-05-31
PL3207039T3 (pl) 2019-08-30
KR20170066651A (ko) 2017-06-14
PH12017500595A1 (en) 2017-08-30
TW201629048A (zh) 2016-08-16
CN107108587B (zh) 2020-05-22
EA201790830A1 (ru) 2017-09-29
BR112017005859A2 (pt) 2017-12-26
IL251200A0 (en) 2017-05-29
NZ729688A (en) 2020-05-29
CA2964754A1 (en) 2016-04-21
AU2015333611A1 (en) 2017-03-23
DK3207039T3 (en) 2019-04-23
ES2724555T3 (es) 2019-09-12
IL251200B (en) 2019-05-30
HUE043783T2 (hu) 2019-09-30
PT3207039T (pt) 2019-06-04
CA2964754C (en) 2023-01-24
US20160108026A1 (en) 2016-04-21
EP3207039A1 (en) 2017-08-23
TR201907755T4 (tr) 2019-06-21

Similar Documents

Publication Publication Date Title
CY1125051T1 (el) Συντηγμενη ενωση αναστολεα jak ιμιδαζο-πιπεριδινης
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1126109T1 (el) Αναστολεις toy trpc6
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
CY1120846T1 (el) 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1
CY1120715T1 (el) Παραγωγα ετεροαρυλιου βουτανικου οξεος ως αναστολεις lta4h
DOP2017000034A (es) Compuestos de imidazopiridazina
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1122439T1 (el) Κυκλοαλκυλ-συνδεδεμενα παραγωγα δι-ετεροκυκλων
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
CY1120744T1 (el) Παραγωγα οξικου οξεος αζαϊνδολης και η χρηση αυτων ως ρυθμιστων υποδοχεων προσταγλανδινης d2
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam